Zepbound News

The use of weight loss medications in the U.S. has surged significantly, with Bernstein estimating that 15% of adults will utilize these drugs within the next four to five years. This increase is expected to lead to a 1% annual reduction in calorie consumption, particularly impacting the packaged food sector, especially sweet and salty snacks. In Massachusetts, prescriptions for medications like Wegovy and Zepbound rose to approximately 140,400 in 2024, marking a 255% increase from the previous year, according to an analysis of insurance claims data. In the same week, Zepbound prescriptions surpassed those of Wegovy for the first time, with Wegovy scripts declining by 9.4% week over week while Zepbound gained 4.4%. The weight loss drug Wegovy has generated more than $7 billion in revenue over the last 12 months, with sales increasing nearly 20,000% over three years. Additionally, some patients have reported substantial weight loss using GLP-1 medications, with one patient noting a 25% weight reduction and an improved relationship with food.